The findings, which were published in an advance print of the journal JAMA Oncology this month, indicated that the use of Marlborough, Mass.-based Hologic’s 3D mammography unit resulted in less call backs, more cancer cases found in recalled patients and fewer cancers diagnosed between regular screenings.
“The new JAMA Oncology study is a significant addition to the already substantial body of research showing that Genius 3D mammography exams increase invasive cancer detection and reduce the number of women recalled for additional imaging. This new study demonstrates that the benefits of 3D mammography are sustainable, and further supports the importance and need for this life-saving technology,” breast and skeletal health solutions division prez Pete Valenti said in prepared remarks.
During the study, researchers analyzed screening mammography metrics for 23,958 women over 4-years. Study researchers analyzed differences in screening outcomes for women screened with standard digital mammography, women screened with 3D mammography exams and women screened with 3D mammography exams over multiple years, and determined that sustained and improved performance was possible over time when 3D mammography exams were used during population based screenings.
Last month, Hologic saw shares dip slightly after posting its fiscal year 2016 Q1 earnings, beating the street across all points and adjusting earnings per share guidance up.
The company reported profits of $84.9 million, or 29¢ per share, on sales of $695.2 million for the 3 months ended December 26. That amounts to a substantial 190.8% bottom-line gain on sales growth of 6.5% compared with Q1 2014.
Adjusted to exclude 1-time items, earnings per share were 46¢, beating Wall Street analyst expectations of 42¢. The company handily topped revenue expectations of $688.8 million for the quarter.